RELMADA THERAPEUTICS, INC. (RLMD) Debt Components
- 2020-12-31: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Convertible Notes PayableUSD (m).
- 2020-09-30: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Convertible Notes PayableUSD (m).
- 2020-06-30: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Convertible Notes PayableUSD (m).
- 2020-03-31: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Convertible Notes PayableUSD (m).
RELMADA THERAPEUTICS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Convertible Notes Payable, Current USD | Notes Payable, Current USD | Long-term Line of Credit USD | Convertible Notes Payable USD | Notes Payable USD | Line of Credit Facility, Increase (Decrease), Net USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Interest Rate, Effective Percentage pure | Debt Instrument, Interest Rate During Period pure | Debt Instrument, Convertible, Beneficial Conversion Feature USD | Debt Instrument, Convertible, Conversion Price USD/shares | Debt Instrument, Decrease, Forgiveness USD | Debt Instrument, Unamortized Discount, Noncurrent USD | Debt Instrument, Unamortized Discount USD | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $110.25K | (m) | (m) | $110.20K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
| 2019-09-30 | (m) | $255.93K | (m) | (m) | $255.90K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $364.20K | (m) | (m) | $364.20K | (m) | 3.09% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
| 2019-03-31 | (m) | $28.77K | (m) | (m) | $28.80K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
| 2018-12-31 | (m) | $114.74K | (m) | (m) | $114.70K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
| 2018-10-31 | (m) | (m) | (m) | $7.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-10-18 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · 7.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-10-18 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · 7.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-10-18 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.89M | (m) |
| 2018-10-12 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 7.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $200.20K | (m) | (m) | $200.20K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.01M | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | 2.35% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $285.17K | (m) | $7.21M | $285.20K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.55M | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 0.75 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $27.88K | (m) | $7.21M | $27.90K | (m) | (m) | (m) | (m) | (m) | 0.75 | (m) | $5.63M | (m) | (m) |
| 2017-12-31 | (m) | $111.23K | (m) | (m) | $111.02K | (m) | (m) | (m) | (m) | (m) | 0.75 | (m) | $6.11M | (m) | (m) |
| 2017-11-30 | (m) | (m) | (m) | $585.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-10-31 | (m) | (m) | (m) | $2.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | $4.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $194.16K | (m) | (m) | $194.20K | (m) | 7.00% | (m) | (m) | (m) | 0.75 | (m) | $3.80M | (m) | (m) |
| 2017-06-30 | (m) | $276.67K | (m) | (m) | $276.70K | (m) | 2.05% | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
| 2017-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | 9 month · $234.40K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $27.58K | $392.60K | (m) | $27.60K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | 6 month · $234.40K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $110.03K | $392.60K | (m) | $110.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | 3 month · $234.40K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $164.44K | $392.60K | (m) | $164.40K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | 2.10% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $273.67K | $390.80K | (m) | $273.70K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $88.53K | (m) | (m) | $88.50K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $176.45K | (m) | (m) | $176.40K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | 2.80% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $263.75K | (m) | (m) | $263.80K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $390.80K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 2.95% | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $38.09K | (m) | (m) | (m) | (m) | (m) | 2.95% | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $148.32K | (m) | (m) | (m) | (m) | (m) | (m) | 2.95% | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-07-31 | (m) | (m) | (m) | (m) | (m) | (m) | 3.00% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $186.73K | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $58.36K | (m) | (m) | $58.40K | (m) | 3.40% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $58.36K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 8.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $844.29K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $55.08K | (m) |
| 2013-12-31 | (m) | $758.95K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $141.05K | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 8.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 10.00% | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $353.25K | (m) | (m) | (m) |
| 2012-12-31 | (m) | $153.68K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $62.33K | (m) |
| 2012-04-30 | (m) | (m) | $975.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-04-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $975.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |